Direct Therapeutics, Inc. Company Profile

00:11 EDT 23rd October 2017 | BioPortfolio

Direct Therapeutics, Inc. is a development-stage pharmaceutical company using its patented Solvent-Facilitated Perfusion technology to create new drugs for the localized and regional treatment of solid-tumor cancers. Our products are designed for direct injection to target tissue with minimal invasion of healthy tissue. They contain active ingredients in organic solvent vehicles that facilitate the penetration of the drug throughout tumor tissue and into tumor cells. In contrast to "sustained release" or "controlled release" products, our products rapidly, selectively, and thoroughly saturate tumors with doses of potent chemotherapeutic agents unachievable by other means. We have demonstrated that these products, when directly applied by needle or catheter to solid tumors, perfuse preferentially throughout the tumor, leading to rapid, selective death of cancerous tissue.
We have completed two Phase I/II studies of our lead product, DTI-015 in the United States for the treatment of brain cancer, and will start our first European trial of DTI-015 in Q1 2003. In November 2002 , we received notice from the US FDA that the company had satisfied the necessary requirements to initiate a Phase III product-registration trial of DTI-015 in patients with glioblastoma multiforme, the most common and deadly form of brain cancer. In addition, we are pursuing development of new Solvent-Facilitated Perfusion products, which have shown positive results in pre-clinical studies.


460 Seaport Court, Suite 220
United States of America



News Articles [858 Associated News Articles listed on BioPortfolio]

RDO nets $4mm for Viking Therapeutics

Viking Therapeutics Inc. (focused on metabolic and endocrine disorders) netted $4mm through the registered direct offering of 3.7mm common shares at $1.15 (an 8% discount) to accredited investors. The...

MabVax Therapeutics Announces $500,000 Registered Direct Offering

SAN DIEGO, Oct. 11, 2017 /PRNewswire/ --MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet...

MabVax Therapeutics Announces Pricing Of Registered Direct Offering

  Life Sciences Jobs   ...

MabVax Therapeutics Announces $2.0 Million Registered Direct Offering

  Life Sciences Jobs   ...

MabVax Therapeutics Announces $1.25 Million Registered Direct Offering

  Life Sciences Jobs   ...

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

MabVax Therapeutics Announces The Closing Of $1.3 Million Registered Direct Offering And Is Engaging An Advisory Bank To Explore Strategic Alternatives

  Life Sciences Jobs   ...

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

PubMed Articles [1066 Associated PubMed Articles listed on BioPortfolio]

Letter: the potential risk of HBV reactivation in patients with resolved HBV infection during direct-acting antiviral therapy.

Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.

In the era of highly effective direct-acting antivirals (DAAs) for treatment of patients with chronic hepatitis C virus (HCV) infection, ribavirin (RBV) is still considered beneficial in certain patie...

Letter: the potential risk of HBV reactivation in patients with resolved HBV infection during direct-acting antiviral therapy - authors' reply.

Differential Intraocular Pressure Measurements by Tonometry and Direct Cannulation After Treatment with Soluble Adenylyl Cyclase Inhibitors.

To validate the increase in intraocular pressure (IOP) caused by soluble adenylyl cyclase (sAC) inhibitors and determine reasons behind variation in IOP measurements performed by tonometry.

A Novel Neuroprotective Small Molecule for Glial Cell Derived Neurotrophic Factor Induction and Photoreceptor Rescue.

Degenerative diseases of the retina, such as retinitis pigmentosa and age-related macular degeneration, are characterized by the irreversible loss of photoreceptors. Several growth factors, including ...

Clinical Trials [1156 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Direct Anterior Approach Versus Direct Lateral Approach in Total Hip Arthroplasty

The purpose of this study is to compare the direct anterior approach and the direct lateral approach in primary total hip arthroplasty, regarding the postoperative function and pain, compl...

Companies [1733 Associated Companies listed on BioPortfolio]


ING DIRECT USA, the nation's largest direct bank and largest thrift, is dedicated to inspiring Americans to become a nation of savers. Since its inception in 2000, more than 7.6 million Americans have...

NX Direct

NX Direct is a sales and consulting firm in Atlanta, Georgia, that specializes in direct marketing and customer acquisition and retention campaigns. NX Direct represents their cli...

Direct Capital Corp.

Established in 1993, Direct Capital provides specialty finance solutions, including capital equipment leasing, commercial loans, and merchant cash advances. Direct Capital markets...

Coley Pharmaceutical Group

Our proprietary TLR Therapeutics™ act by stimulating a specific class of targets, called Toll-like receptors, or TLRs, found in and on immune system cells which, in turn, direct the immune system to...

Viventia Biotech Inc.

Viventia Biotech Inc. is a leader in developing innovative therapeutics based upon the human immune response to cancer. Through its Hybridomics™ discovery platform and ImmunoMine™ screening techno...

More Information about "Direct Therapeutics, Inc." on BioPortfolio

We have published hundreds of Direct Therapeutics, Inc. news stories on BioPortfolio along with dozens of Direct Therapeutics, Inc. Clinical Trials and PubMed Articles about Direct Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Direct Therapeutics, Inc. Companies in our database. You can also find out about relevant Direct Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Corporate Database Quicklinks

Searches Linking to this Company Record